MAIA Biotechnology, Inc. — Form 8-K
Filed November 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
MAIA Biotechnology announced interim efficacy data from Part C of its Phase 2 THIO-101 trial of ateganosine (telomere-targeting agent) in third-line non-small cell lung cancer. Combined data from Parts A, B, and C show 88% disease control rate (38 of 43 patients) as of October 1, 2026, substantially exceeding the 25–35% DCR for standard third-line chemotherapy. The company is completing Part C enrollment across seven countries and advancing the pivotal Phase 3 THIO-104 trial toward 2027 interim survival analysis.
Why this rating
Clinical efficacy data materially advance lead asset relative to company scale ($48.9M market cap). Phase 3 initiation and Fast Track status de-risk regulatory path; magnitude of DCR advantage (88% vs. 25–35%) is compelling for late-stage cancer therapy but remains early-stage (Phase 2 interim). Stock-price-positive news, though regulatory and OS confirmation remain critical unknowns.
Tradability signal
NO TRADE
No trade: already up 8.3% on the news and the fade evidence is too weak. Similar past filings (543 in this cell) moved -0.26% in the called direction over 4 hrs; shrunk for sample size that's a -0.25% edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.02 ▲ 0.99% | at our read · unknown $1.01 | +10 min · unknown $1.10 ▲ 8.91% | +30 min · unknown $1.11 ▲ 9.90% | +1 hr · unknown $1.15 ▲ 13.86% | +4 hrs · unknown $1.23 ▲ 21.29% |
The stock had already moved -0.98% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.